Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 17Ovarian Neoplasms 16Fallopian Tube Neoplasms 12Neoplasm Metastasis 10Triple Negative Breast Neoplasms 7Prostatic Neoplasms 7Neoplasms 7Endometrial Neoplasms 6Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neuroendocrine Tumors 3Metastatic Castration-resistant Prostate Cancer 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Sarcoma 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Osteosarcoma 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2

Interventions

olaparib 1Early Intervention, Educational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate × olaparib × 90 days × Clear all
NCT03047135 2026-05-12

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
51 enrolled 8 charts
Genitourinary

Prostate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡